IMMU is trying to rally after forming a good base at the $3.10 level.<g>
bigcharts.marketwatch.com
It announced today that its patent for "Immunotherapy of autoimmune disorders using antibodies which target B-cells" has been issued as U.S. patent no. 7,641,901.
The patent covers the use of monoclonal antibodies that bind to the CD22 antigen on B-lymphocytes for treating autoimmune disorders.
The stock is up 26.61% with volume now > 17M. It seems it could get to 10x its ADV since there is a good amount of short covering. (The SI was up 20% and about 6.7x the ADV <g>)
The allowed claims cover the use of epratuzumab, its proprietary humanized anti-CD22 monoclonal antibody, and other anti-CD22 antibodies, alone and in combination with other therapeutics, such as antibodies, cytokines, or drugs, for the treatment of a wide range of autoimmune diseases that include systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, multiple sclerosis, myasthenia gravis, diabetes mellitus, and ulcerative colitis.
The resistance to watch is at the $5 to $5.10 level.<g>
bigcharts.marketwatch.com
Bernard |
